126 related articles for article (PubMed ID: 25885920)
21. Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study.
Rizzo M; Facchini G; Savastano C; Di Lorenzo G; Lucia LD; Maiorino L; Casale B; Grimaldi G; Formato R; Febbraro A; Cartenì G
Future Oncol; 2015; 11(2):219-24. PubMed ID: 25078333
[TBL] [Abstract][Full Text] [Related]
22. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.
Alimohamed N; Lee JL; Srinivas S; Bjarnason GA; Knox JJ; Mackenzie MJ; Wood L; Vaishampayan UN; Tan MH; Rha SY; Donskov F; Tantravahi S; Kollmannsberger C; North S; Rini BI; Choueiri TK; Heng DY
Clin Genitourin Cancer; 2014 Aug; 12(4):e127-31. PubMed ID: 24485801
[TBL] [Abstract][Full Text] [Related]
23. Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study.
Bergmann L; Goebell PJ; Kube U; Kindler M; Herrmann E; Janssen J; Schmitz J; Weikert S; Steiner G; Jakob A; Staehler MD; Steiner T; Overkamp F; Albrecht M; Guderian G; Doehn C
Onkologie; 2013; 36(3):95-100. PubMed ID: 23485996
[TBL] [Abstract][Full Text] [Related]
24. Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
Pal SK; Signorovitch JE; Reichmann WM; Li N; Koo V; Liu Z; Perez JR; Vogelzang NJ
Clin Genitourin Cancer; 2016 Apr; 14(2):160-7.e3. PubMed ID: 26707954
[TBL] [Abstract][Full Text] [Related]
25. REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis.
Bracarda S; Rottey S; Bahl A; Eichelberg C; Mellado B; Mangel L; Cattaneo A; Panneerselvam A; Grünwald V
Future Oncol; 2015; 11(21):2893-903. PubMed ID: 26376939
[TBL] [Abstract][Full Text] [Related]
26. Post-marketing observational study of everolimus in patients with unresectable or metastatic renal cell carcinoma in Japan.
Akaza H; Kurihara R; Katsura A; Harumiya M; Ushida N
Jpn J Clin Oncol; 2019 Oct; 49(10):956-964. PubMed ID: 31135920
[TBL] [Abstract][Full Text] [Related]
27. Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimus.
Amato RJ; Flaherty A; Zhang Y; Ouyang F; Mohlere V
Urol Oncol; 2014 Apr; 32(3):345-54. PubMed ID: 24321256
[TBL] [Abstract][Full Text] [Related]
28. Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma.
Thiery-Vuillemin A; Laheurte C; Mansi L; Royer B; Pivot X; Borg C; Adotevi O
J Immunother; 2014 Jan; 37(1):51-4. PubMed ID: 24316556
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Urbanowitz G; Berg WJ; Kay A; Lebwohl D; Ravaud A;
Lancet; 2008 Aug; 372(9637):449-56. PubMed ID: 18653228
[TBL] [Abstract][Full Text] [Related]
30. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
31. Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma.
Voss MH; Chen D; Marker M; Hakimi AA; Lee CH; Hsieh JJ; Knox JJ; Voi M; Motzer RJ
Br J Cancer; 2016 Mar; 114(6):642-9. PubMed ID: 26908330
[TBL] [Abstract][Full Text] [Related]
32. Lenvatinib/everolimus improves survival better than everolimus alone in metastatic renal cell cancer.
Clin Adv Hematol Oncol; 2015 Aug; 13(8):512-3. PubMed ID: 26351813
[No Abstract] [Full Text] [Related]
33. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis.
Buchler T; Bortlicek Z; Poprach A; Kubackova K; Kiss I; Zemanova M; Fiala O; Dusek L; Vyzula R; Melichar B;
Urol Oncol; 2014 Jul; 32(5):569-75. PubMed ID: 24629497
[TBL] [Abstract][Full Text] [Related]
35. Role of WNT/β-Catenin Pathway as Potential Prognostic and Predictive Factors in Renal Cell Cancer Patients Treated With Everolimus in the Second and Subsequent Lines.
Bodnar L; Stec R; Cierniak S; Synowiec A; Wcisło G; Jesiotr M; Koktysz R; Chrom P; Szczylik C
Clin Genitourin Cancer; 2018 Aug; 16(4):257-265. PubMed ID: 29483043
[TBL] [Abstract][Full Text] [Related]
36. The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib.
Basappa NS; Elson P; Golshayan AR; Wood L; Garcia JA; Dreicer R; Rini BI
Cancer; 2011 Mar; 117(6):1183-9. PubMed ID: 20960527
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic value of toxicities induced by targeted therapies in patients treated for a metastatic renal cell carcinoma].
Nouhaud FX; Rebibo JD; Blanchard F; Sabourin JC; Di Fiore F; Pfister C
Prog Urol; 2014 Jul; 24(9):563-71. PubMed ID: 24975791
[TBL] [Abstract][Full Text] [Related]
38. Everolimus for the treatment of advanced renal cell carcinoma.
Amato R
Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
[TBL] [Abstract][Full Text] [Related]
39. Retrospective analyses of patient characteristics having predictive impact on survival under everolimus.
Seidel C; Fenner M; Reuter C; Merseburger AS; Ganser A; Grünwald V
Onkologie; 2011; 34(3):111-4. PubMed ID: 21358215
[TBL] [Abstract][Full Text] [Related]
40. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
Busch J; Seidel C; Kempkensteffen C; Johannsen M; Wolff I; Hinz S; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2011 Dec; 60(6):1163-70. PubMed ID: 21802830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
